MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will host an earnings call on May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022. The call aims to provide investors with updates on the company's performance and business developments. MindMed focuses on developing products for brain health, particularly in psychiatry, addiction, pain, and neurology. The company is committed to improving patient outcomes through innovative drug candidates targeting critical neurotransmitter systems.
- MindMed is focused on developing treatments for brain health disorders, including in psychiatry and addiction.
- The upcoming earnings call indicates a proactive approach to investor communication.
- No financial results or specific performance metrics are provided ahead of the earnings call.
NEW YORK, May 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
Individuals may participate via telephone by dialing (877) 407-0789 (domestic) or (201) 689-8562 (international) and using conference ID 13729397. The webcast can be accessed live here or on MindMed's Investor Resources webpage. The webcast will be archived on the company's website for at least 30 days after the conference call.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-host-earnings-call-to-discuss-first-quarter-2022-financial-results-and-provide-business-update-301542337.html
SOURCE Mind Medicine (MindMed), Inc.
FAQ
When will MindMed's next earnings call take place?
What financial results will MindMed discuss in the upcoming earnings call?
How can I participate in MindMed's earnings call?
What is the focus of MindMed's drug development?
